{"entity":{"id":"nct06373406","kind":"trial","name":"A Study of MHB036C for Advanced Solid Tumor","aka":[],"tldr":"A phase 1/2 trial of MHB036C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.","summary":"A Study of MHB036C for Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06373406 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants enrolled, started 2023-05-26 and due to reach its primary completion in 2025-12. Interventions recorded: MHB036C.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06373406","url":"https://clinicaltrials.gov/study/NCT06373406"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06373406","phase":"1/2","setting":"A Phase I/II, Dose Escalation and Dose Expansion Study of MHB036C for Advanced Solid Tumor to Evaluate the Tolerability/Safety, Pharmacokinetics and Efficacy","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","enrolled":200,"outcomes":[]},"route":"/trials/nct06373406/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"mhb036c","kind":"drug","name":"MHB036C","route":"/drugs/mhb036c/"}]}}